Overview

A Phase II Study of Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Status:
Active, not recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Afatinib